Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 18/20 | 0.36 |
| ▸ | CA2 | P00918 | 18/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3812152 | 0.90 | NOS3 (0.39) | NOS3NOS1NOS2CA1CA2 | |
| Water SCHEMBL21810558 | 0.88 | NOS3 (0.38) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL5326458 | 0.86 | NOS3 (0.37) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL449032 | 0.85 | NOS3 (0.34) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL941222 | 0.84 | ALDH1A1 (0.38) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL21404061 | 0.84 | CA1 (0.39) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL5686362 | 0.83 | CA1 (0.33) | NOS3NOS1NOS2CA1CA2 | |
| Water SCHEMBL8466789 | 0.83 | CA1 (0.33) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL5345186 | 0.82 | CA1 (0.36) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL584167 | 0.82 | NOS3 (0.35) | NOS3NOS1NOS2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10888719-B2 | Active substance combination of creatine and/or creatinine and phenoxyethanol | BEIERSDORF AG (DE) | 2021-01-12 | — | — | US | claimed |
| US-10682534-B2 | Cosmetic preparations containing creatine and/or creatinine and organic thickeners | BEIERSDORF, AG (DE) | 2020-06-16 | — | — | US | claimed |
| EP-1642559-B1 | Use of creatine and/or creatine derivatives and folic acid in cosmetic or dermatological preparations | BEIERSDORF AG (DE) | 2018-04-04 | — | — | EP | claimed |
| US-20140171682-A1 | Creatine hydrochloride and manufacturing method thereof | Tianjin Tiancheng Pharmaceutical Co., Ltd (China) | 2014-06-19 | — | — | US | claimed |
| EP-1885328-B1 | ACTIVE INGREDIENT COMBINATIONS OF GLUCOSYL GLYCERIDES AND CREATINE AND/OR CREATININE | BEIERSDORF AG (DE) | 2012-08-01 | — | — | EP | claimed |
| EP-1296642-B1 | USE OF CREATINE AND/OR CREATINE DERIVATIVES IN DERMATOLOGICAL PREPARATIONS | BEIERSDORF AG (DE) | 2011-10-26 | — | — | EP | claimed |
| US-20090137497-A1 | ACTIVE INGREDIENT COMBINATIONS OF GLUCOSYL GLYCERIDES AND CREATINE AND/OR CREATININE | BEIERSDORF AG (DE) | 2009-05-28 | — | — | US | claimed |
| EP-1406599-B1 | COSMETIC AND DERMATOLOGICAL PREPARATIONS CONTAINING CREATINE FOR TREATING AND ACTIVELY PREVENTING DRY SKIN AND OTHER NEGATIVE ALTERATIONS OF THE PHYSIOLOGICAL HOMEOSTASIS OF HEALTHY SKIN | BEIERSDORF AG (DE) | 2009-04-15 | — | — | EP | claimed |
| US-20060241021-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | UNIVERSITY OF CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2006-10-26 | — | — | US | claimed |
| US-20060018869-A1 | Cosmetic or dermatological preparation with a content of creatine, creatinine or derivatives thereof in combination with soybean germ extract | BEIERSDORF AG | 2006-01-26 | — | — | US | claimed |
| EP-1567180-A2 | METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM | Avicena Group, Inc. (US) | 2005-08-31 | — | — | EP | claimed |
| US-20040258717-A1 | Cosmetic and dermatological preparations containing creatine for treating and actively preventing dry skin and other negative alterations of the physiological homeostasis of the healthy-skin | BEIERSDORF AG (DE) | 2004-12-23 | — | — | US | claimed |
| US-20040241197-A1 | Cosmetic or dermatological preparations including creatinine or a derivative thereof and creatine or a derivative thereof and methods of applying the preparations to the skin | BEIERSDORF AG | 2004-12-02 | — | — | US | claimed |
| US-20040126366-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | CINCINNATI, UNIVERSITY OF | 2004-07-01 | — | — | US | claimed |
| US-20040029969-A1 | Use of creatine or creatine derivatives in cosmetic or dematological preparations | BEIERSDORF AG | 2004-02-12 | — | — | US | claimed |
| WO-2003101402-A2 | METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM | AVICENA GROUP, INC. (US) | 2003-12-11 | — | — | WO | claimed |
| EP-4719464-A1 | TREATMENT OF TYPE 1 DIABETES (T1D) WITH TOLERIZING NANOPARTICLES | Cour Pharmaceuticals Development Company Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4687970-A1 | TOLERIZING IMMUNE MODIFYING NANOPARTICLES FOR MYASTHENIA GRAVIS TREATMENT | Cour Pharmaceuticals Development Company Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20020182234-A1 | Self-foaming or foam-like preparations | BEIERSDORF AKTIENGESELLSCHAFT | 2002-12-05 | — | — | US | disclosed |
| US-20020102289-A1 | Cosmetic or dermatological impregnated wipes | BEIERSDORF AG (DE) | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171682-A1 | Creatine hydrochloride and manufacturing method thereof | CKMT1A; CKMT1B, CRAT, PRKCE | NOS3 3200/4885NOS1 3050/4885NOS2 3270/4885 |
| US-20020182234-A1 | Self-foaming or foam-like preparations | FFAR2, LIPA, FFAR1 | NOS3 70/4885NOS1 47/4885NOS2 26/4885 |
| US-20020102289-A1 | Cosmetic or dermatological impregnated wipes | CUTA, PWWP2B, WIZ | NOS3 2959/4885NOS1 1540/4885NOS2 1754/4885 |
| US-20060241021-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | PC, PYGB, PCK2 | NOS3 728/4885NOS1 822/4885NOS2 694/4885 |
| US-10888719-B2 | Active substance combination of creatine and/or creatinine and phenoxyethanol | REN, CKMT1A; CKMT1B, CRAT | NOS3 2337/4885NOS1 2930/4885NOS2 2431/4885 |
| US-20040241197-A1 | Cosmetic or dermatological preparations including creatinine or a derivative thereof and creatine or a derivative thereof and methods of applying the preparations to the skin | CUTA, CKMT1A; CKMT1B, REN | NOS3 1747/4885NOS1 1826/4885NOS2 1723/4885 |
| US-20090137497-A1 | ACTIVE INGREDIENT COMBINATIONS OF GLUCOSYL GLYCERIDES AND CREATINE AND/OR CREATININE | GK, GLA, GRHPR | NOS3 3744/4885NOS1 3487/4885NOS2 3432/4885 |
| US-10682534-B2 | Cosmetic preparations containing creatine and/or creatinine and organic thickeners | CKMT1A; CKMT1B, OTC, CRAT | NOS3 1186/4885NOS1 1943/4885NOS2 1281/4885 |
| US-20040126366-A1 | Methods of treating cognitive dysfunction by modulating brain energy metabolism | PC, PYGB, PCK2 | NOS3 728/4885NOS1 822/4885NOS2 694/4885 |
| US-20040029969-A1 | Use of creatine or creatine derivatives in cosmetic or dematological preparations | CKMT1A; CKMT1B, RARS2, CRAT | NOS3 1272/4885NOS1 1370/4885NOS2 1300/4885 |
| US-20060018869-A1 | Cosmetic or dermatological preparation with a content of creatine, creatinine or derivatives thereof in combination with soybean germ extract | CKMT1A; CKMT1B, AGER, CUTA | NOS3 2452/4885NOS1 2423/4885NOS2 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.